Search

Your search keyword '"Uzay E"' showing total 19 results
Start Over Author "Uzay E" Publication Type Electronic Resources
19 results on '"Uzay E"'

1. In Vivo Renal Lipid Quantification by Accelerated Magnetic Resonance Spectroscopic Imaging at 3T: Feasibility and Reliability Study.

Author

Alhulail, Ahmad A, Alhulail, Ahmad A, Servati, Mahsa, Ooms, Nathan, Akin, Oguz, Dincer, Alp, Thomas, M Albert, Dydak, Ulrike, Emir, Uzay E, Alhulail, Ahmad A, Alhulail, Ahmad A, Servati, Mahsa, Ooms, Nathan, Akin, Oguz, Dincer, Alp, Thomas, M Albert, Dydak, Ulrike, and Emir, Uzay E

Abstract

A reliable and practical renal-lipid quantification and imaging method is needed. Here, the feasibility of an accelerated MRSI method to map renal fat fractions (FF) at 3T and its repeatability were investigated. A 2D density-weighted concentric-ring-trajectory MRSI was used for accelerating the acquisition of 48 × 48 voxels (each of 0.25 mL spatial resolution) without respiratory navigation implementations. The data were collected over 512 complex-FID timepoints with a 1250 Hz spectral bandwidth. The MRSI sequence was designed with a metabolite-cycling technique for lipid-water separation. The in vivo repeatability performance of the sequence was assessed by conducting a test-reposition-retest study within healthy subjects. The coefficient of variation (CV) in the estimated FF from the test-retest measurements showed a high degree of repeatability of MRSI-FF (CV = 4.3 ± 2.5%). Additionally, the matching level of the spectral signature within the same anatomical region was also investigated, and their intrasubject repeatability was also high, with a small standard deviation (8.1 ± 6.4%). The MRSI acquisition duration was ~3 min only. The proposed MRSI technique can be a reliable technique to quantify and map renal metabolites within a clinically acceptable scan time at 3T that supports the future application of this technique for the non-invasive characterization of heterogeneous renal diseases and tumors.

Published
2022

2. Fast in vivo 23 Na imaging and T2∗ mapping using accelerated 2D-FID UTE magnetic resonance spectroscopic imaging at 3 T: Proof of concept and reliability study.

Author

Alhulail, Ahmad A, Alhulail, Ahmad A, Xia, Pingyu, Shen, Xin, Nichols, Miranda, Volety, Srijyotsna, Farley, Nicholas, Thomas, Micheal Albert, Nagel, Armin M, Dydak, Ulrike, Emir, Uzay E, Alhulail, Ahmad A, Alhulail, Ahmad A, Xia, Pingyu, Shen, Xin, Nichols, Miranda, Volety, Srijyotsna, Farley, Nicholas, Thomas, Micheal Albert, Nagel, Armin M, Dydak, Ulrike, and Emir, Uzay E

Abstract

PurposeTo implement an accelerated MR-acquisition method allowing to map T2∗ relaxation and absolute concentration of sodium within skeletal muscles at 3T.MethodsA fast-UTE-2D density-weighted concentric-ring-trajectory 23 Na-MRSI technique was used to acquire 64 time points of FID with a spectral bandwidth of 312.5 Hz with an in-plane resolution of 2.5 × 2.5 mm2 in ~15 min. The fast-relaxing 23 Na signal was localized with a single-shot, inversion-recovery-based, non-echo (SIRENE) outer volume suppression (OVS) method. The sequence was verified using simulation and phantom studies before implementing it in human calf muscles. To evaluate the 2D-SIRENE-MRSI (UTE = 0.55 ms) imaging performance, it was compared to a 3D-MRI (UTE = 0.3 ms) sequence. Both data sets were acquired within 2 same-day sessions to assess repeatability. The T2∗ values were fitted voxel-by-voxel using a biexponential model for the 2D-MRSI data. Finally, intra-subject coefficients of variation (CV) were estimated.ResultsThe MRSI-FID data allowed us to map the fast and slow components of T2∗ in the calf muscles. The spatial distributions of 23 Na concentration for both MRSI and 3D-MRI acquisitions were significantly correlated (P < .001). The test-retest analysis rendered high repeatability for MRSI with a CV of 5%. The mean T2Fast∗ in muscles was 0.7 ± 0.1 ms (contribution fraction = 37%), whereas T2Slow∗ was 13.2 ± 0.2 ms (63%). The mean absolute muscle 23 Na concentration calculated from the T2∗ -corrected data was 28.6 ± 3.3 mM.ConclusionThe proposed MRSI technique is a reliable technique to map sodium's absolute concentration and T2∗ within a clinically acceptable scan time at 3T.

Published
2021

3. Fat-water separation by fast metabolite cycling magnetic resonance spectroscopic imaging at 3 T: A method to generate separate quantitative distribution maps of musculoskeletal lipid components.

Author

Alhulail, Ahmad A, Alhulail, Ahmad A, Patterson, Debra A, Xia, Pingyu, Zhou, Xiaopeng, Lin, Chen, Thomas, M Albert, Dydak, Ulrike, Emir, Uzay E, Alhulail, Ahmad A, Alhulail, Ahmad A, Patterson, Debra A, Xia, Pingyu, Zhou, Xiaopeng, Lin, Chen, Thomas, M Albert, Dydak, Ulrike, and Emir, Uzay E

Abstract

PurposeTo provide a rapid, noninvasive fat-water separation technique that allows producing quantitative maps of particular lipid components.MethodsThe calf muscles in 5 healthy adolescents (age 12-16 years; body mass index = 20 ± 3 kg/m2 ) were scanned by two different fat fraction measurement methods. A density-weighted concentric-ring trajectory metabolite-cycling MRSI technique was implemented to collect data with a nominal resolution of 0.25 mL within 3 minutes and 16 seconds. For comparative purposes, the standard Dixon technique was performed. The two techniques were compared using structural similarity analysis. Additionally, the difference in the distribution of each lipid over the adolescent calf muscles was assessed based on the MRSI data.ResultsThe proposed MRSI technique provided individual fat fraction maps for eight musculoskeletal lipid components identified by LCModel analysis (IMC/L [CH3 ], EMCL [CH3 ], IMC/L [CH2 ]n , EMC/L [CH2 ]n , IMC/L [CH2 -CH], EMC/L [CH2 -CH], IMC/L [-CH=CH-], and EMC/L [-CH=CH-]) with mean structural similarity indices of 0.19, 0.04, 0.03, 0.50, 0.45, 0.04, 0.07, and 0.12, respectively, compared with the maps generated by the used Dixon method. Further analysis of voxels with zero structural similarity demonstrated an increased sensitivity of fat fraction lipid maps from the data acquired using this MRSI technique over the standard Dixon technique. The lipid spatial distribution over calf muscles was consistent with previously published findings in adults.ConclusionThis MRSI technique can be a useful tool when individual lipid fat fraction maps are desired within a clinically acceptable time and with a nominal spatial resolution of 0.25 mL.

Published
2020

4. Non-water-suppressed short-echo-time magnetic resonance spectroscopic imaging using a concentric ring k-space trajectory.

Author

Emir, Uzay E, Emir, Uzay E, Burns, Brian, Chiew, Mark, Jezzard, Peter, Thomas, M Albert, Emir, Uzay E, Emir, Uzay E, Burns, Brian, Chiew, Mark, Jezzard, Peter, and Thomas, M Albert

Abstract

Water-suppressed MRS acquisition techniques have been the standard MRS approach used in research and for clinical scanning to date. The acquisition of a non-water-suppressed MRS spectrum is used for artefact correction, reconstruction of phased-array coil data and metabolite quantification. Here, a two-scan metabolite-cycling magnetic resonance spectroscopic imaging (MRSI) scheme that does not use water suppression is demonstrated and evaluated. Specifically, the feasibility of acquiring and quantifying short-echo (TE = 14 ms), two-dimensional stimulated echo acquisition mode (STEAM) MRSI spectra in the motor cortex is demonstrated on a 3 T MRI system. The increase in measurement time from the metabolite-cycling is counterbalanced by a time-efficient concentric ring k-space trajectory. To validate the technique, water-suppressed MRSI acquisitions were also performed for comparison. The proposed non-water-suppressed metabolite-cycling MRSI technique was tested for detection and correction of resonance frequency drifts due to subject motion and/or hardware instability, and the feasibility of high-resolution metabolic mapping over a whole brain slice was assessed. Our results show that the metabolite spectra and estimated concentrations are in agreement between non-water-suppressed and water-suppressed techniques. The achieved spectral quality, signal-to-noise ratio (SNR) > 20 and linewidth <7 Hz allowed reliable metabolic mapping of five major brain metabolites in the motor cortex with an in-plane resolution of 10 × 10 mm2 in 8 min and with a Cramér-Rao lower bound of less than 20% using LCModel analysis. In addition, the high SNR of the water peak of the non-water-suppressed technique enabled voxel-wise single-scan frequency, phase and eddy current correction. These findings demonstrate that our non-water-suppressed metabolite-cycling MRSI technique can perform robustly on 3 T MRI systems and within a clinically feasible acquisition time.

Published
2017

5. Non-water-suppressed short-echo-time magnetic resonance spectroscopic imaging using a concentric ring k-space trajectory.

Author

Emir, Uzay E, Emir, Uzay E, Burns, Brian, Chiew, Mark, Jezzard, Peter, Thomas, M Albert, Emir, Uzay E, Emir, Uzay E, Burns, Brian, Chiew, Mark, Jezzard, Peter, and Thomas, M Albert

Abstract

Water-suppressed MRS acquisition techniques have been the standard MRS approach used in research and for clinical scanning to date. The acquisition of a non-water-suppressed MRS spectrum is used for artefact correction, reconstruction of phased-array coil data and metabolite quantification. Here, a two-scan metabolite-cycling magnetic resonance spectroscopic imaging (MRSI) scheme that does not use water suppression is demonstrated and evaluated. Specifically, the feasibility of acquiring and quantifying short-echo (TE  = 14 ms), two-dimensional stimulated echo acquisition mode (STEAM) MRSI spectra in the motor cortex is demonstrated on a 3 T MRI system. The increase in measurement time from the metabolite-cycling is counterbalanced by a time-efficient concentric ring k-space trajectory. To validate the technique, water-suppressed MRSI acquisitions were also performed for comparison. The proposed non-water-suppressed metabolite-cycling MRSI technique was tested for detection and correction of resonance frequency drifts due to subject motion and/or hardware instability, and the feasibility of high-resolution metabolic mapping over a whole brain slice was assessed. Our results show that the metabolite spectra and estimated concentrations are in agreement between non-water-suppressed and water-suppressed techniques. The achieved spectral quality, signal-to-noise ratio (SNR) > 20 and linewidth <7 Hz allowed reliable metabolic mapping of five major brain metabolites in the motor cortex with an in-plane resolution of 10 × 10 mm2 in 8 min and with a Cramér-Rao lower bound of less than 20% using LCModel analysis. In addition, the high SNR of the water peak of the non-water-suppressed technique enabled voxel-wise single-scan frequency, phase and eddy current correction. These findings demonstrate that our non-water-suppressed metabolite-cycling MRSI technique can perform robustly on 3 T MRI systems and within a

Published
2017

6. Methodological consensus on clinical proton MRS of the brain: Review and recommendations.

Author

Wilson, Martin, Wilson, Martin, Andronesi, Ovidiu, Barker, Peter B, Bartha, Robert, Bizzi, Alberto, Bolan, Patrick J, Brindle, Kevin M, Choi, In-Young, Cudalbu, Cristina, Dydak, Ulrike, Emir, Uzay E, Gonzalez, Ramon G, Gruber, Stephan, Gruetter, Rolf, Gupta, Rakesh K, Heerschap, Arend, Henning, Anke, Hetherington, Hoby P, Huppi, Petra S, Hurd, Ralph E, Kantarci, Kejal, Kauppinen, Risto A, Klomp, Dennis WJ, Kreis, Roland, Kruiskamp, Marijn J, Leach, Martin O, Lin, Alexander P, Luijten, Peter R, Marjańska, Małgorzata, Maudsley, Andrew A, Meyerhoff, Dieter J, Mountford, Carolyn E, Mullins, Paul G, Murdoch, James B, Nelson, Sarah J, Noeske, Ralph, Öz, Gülin, Pan, Julie W, Peet, Andrew C, Poptani, Harish, Posse, Stefan, Ratai, Eva-Maria, Salibi, Nouha, Scheenen, Tom WJ, Smith, Ian CP, Soher, Brian J, Tkáč, Ivan, Vigneron, Daniel B, Howe, Franklyn A, Wilson, Martin, Wilson, Martin, Andronesi, Ovidiu, Barker, Peter B, Bartha, Robert, Bizzi, Alberto, Bolan, Patrick J, Brindle, Kevin M, Choi, In-Young, Cudalbu, Cristina, Dydak, Ulrike, Emir, Uzay E, Gonzalez, Ramon G, Gruber, Stephan, Gruetter, Rolf, Gupta, Rakesh K, Heerschap, Arend, Henning, Anke, Hetherington, Hoby P, Huppi, Petra S, Hurd, Ralph E, Kantarci, Kejal, Kauppinen, Risto A, Klomp, Dennis WJ, Kreis, Roland, Kruiskamp, Marijn J, Leach, Martin O, Lin, Alexander P, Luijten, Peter R, Marjańska, Małgorzata, Maudsley, Andrew A, Meyerhoff, Dieter J, Mountford, Carolyn E, Mullins, Paul G, Murdoch, James B, Nelson, Sarah J, Noeske, Ralph, Öz, Gülin, Pan, Julie W, Peet, Andrew C, Poptani, Harish, Posse, Stefan, Ratai, Eva-Maria, Salibi, Nouha, Scheenen, Tom WJ, Smith, Ian CP, Soher, Brian J, Tkáč, Ivan, Vigneron, Daniel B, and Howe, Franklyn A

Abstract

Proton MRS (1 H MRS) provides noninvasive, quantitative metabolite profiles of tissue and has been shown to aid the clinical management of several brain diseases. Although most modern clinical MR scanners support MRS capabilities, routine use is largely restricted to specialized centers with good access to MR research support. Widespread adoption has been slow for several reasons, and technical challenges toward obtaining reliable good-quality results have been identified as a contributing factor. Considerable progress has been made by the research community to address many of these challenges, and in this paper a consensus is presented on deficiencies in widely available MRS methodology and validated improvements that are currently in routine use at several clinical research institutions. In particular, the localization error for the PRESS localization sequence was found to be unacceptably high at 3 T, and use of the semi-adiabatic localization by adiabatic selective refocusing sequence is a recommended solution. Incorporation of simulated metabolite basis sets into analysis routines is recommended for reliably capturing the full spectral detail available from short TE acquisitions. In addition, the importance of achieving a highly homogenous static magnetic field (B0 ) in the acquisition region is emphasized, and the limitations of current methods and hardware are discussed. Most recommendations require only software improvements, greatly enhancing the capabilities of clinical MRS on existing hardware. Implementation of these recommendations should strengthen current clinical applications and advance progress toward developing and validating new MRS biomarkers for clinical use.

Published
2019

7. Methodological consensus on clinical proton MRS of the brain : Review and recommendations

Author

Wilson, Martin, Andronesi, Ovidiu, Barker, Peter B., Bartha, Robert, Bizzi, Alberto, Bolan, Patrick J., Brindle, Kevin M., Choi, In Young, Cudalbu, Cristina, Dydak, Ulrike, Emir, Uzay E., Gonzalez, Ramon G., Gruber, Stephan, Gruetter, Rolf, Gupta, Rakesh K., Heerschap, Arend, Henning, Anke, Hetherington, Hoby P., Huppi, Petra S., Hurd, Ralph E., Kantarci, Kejal, Kauppinen, Risto A., Klomp, Dennis W.J., Kreis, Roland, Kruiskamp, Marijn J., Leach, Martin O., Lin, Alexander P., Luijten, Peter R., Marjańska, Małgorzata, Maudsley, Andrew A., Meyerhoff, Dieter J., Mountford, Carolyn E., Mullins, Paul G., Murdoch, James B., Nelson, Sarah J., Noeske, Ralph, Öz, Gülin, Pan, Julie W., Peet, Andrew C., Poptani, Harish, Posse, Stefan, Ratai, Eva Maria, Salibi, Nouha, Scheenen, Tom W.J., Smith, Ian C.P., Soher, Brian J., Tkáč, Ivan, Vigneron, Daniel B., Howe, Franklyn A., Wilson, Martin, Andronesi, Ovidiu, Barker, Peter B., Bartha, Robert, Bizzi, Alberto, Bolan, Patrick J., Brindle, Kevin M., Choi, In Young, Cudalbu, Cristina, Dydak, Ulrike, Emir, Uzay E., Gonzalez, Ramon G., Gruber, Stephan, Gruetter, Rolf, Gupta, Rakesh K., Heerschap, Arend, Henning, Anke, Hetherington, Hoby P., Huppi, Petra S., Hurd, Ralph E., Kantarci, Kejal, Kauppinen, Risto A., Klomp, Dennis W.J., Kreis, Roland, Kruiskamp, Marijn J., Leach, Martin O., Lin, Alexander P., Luijten, Peter R., Marjańska, Małgorzata, Maudsley, Andrew A., Meyerhoff, Dieter J., Mountford, Carolyn E., Mullins, Paul G., Murdoch, James B., Nelson, Sarah J., Noeske, Ralph, Öz, Gülin, Pan, Julie W., Peet, Andrew C., Poptani, Harish, Posse, Stefan, Ratai, Eva Maria, Salibi, Nouha, Scheenen, Tom W.J., Smith, Ian C.P., Soher, Brian J., Tkáč, Ivan, Vigneron, Daniel B., and Howe, Franklyn A.

Published
2019

8. Methodological consensus on clinical proton MRS of the brain : Review and recommendations

Author

Wilson, Martin, Andronesi, Ovidiu, Barker, Peter B., Bartha, Robert, Bizzi, Alberto, Bolan, Patrick J., Brindle, Kevin M., Choi, In Young, Cudalbu, Cristina, Dydak, Ulrike, Emir, Uzay E., Gonzalez, Ramon G., Gruber, Stephan, Gruetter, Rolf, Gupta, Rakesh K., Heerschap, Arend, Henning, Anke, Hetherington, Hoby P., Huppi, Petra S., Hurd, Ralph E., Kantarci, Kejal, Kauppinen, Risto A., Klomp, Dennis W.J., Kreis, Roland, Kruiskamp, Marijn J., Leach, Martin O., Lin, Alexander P., Luijten, Peter R., Marjańska, Małgorzata, Maudsley, Andrew A., Meyerhoff, Dieter J., Mountford, Carolyn E., Mullins, Paul G., Murdoch, James B., Nelson, Sarah J., Noeske, Ralph, Öz, Gülin, Pan, Julie W., Peet, Andrew C., Poptani, Harish, Posse, Stefan, Ratai, Eva Maria, Salibi, Nouha, Scheenen, Tom W.J., Smith, Ian C.P., Soher, Brian J., Tkáč, Ivan, Vigneron, Daniel B., Howe, Franklyn A., Wilson, Martin, Andronesi, Ovidiu, Barker, Peter B., Bartha, Robert, Bizzi, Alberto, Bolan, Patrick J., Brindle, Kevin M., Choi, In Young, Cudalbu, Cristina, Dydak, Ulrike, Emir, Uzay E., Gonzalez, Ramon G., Gruber, Stephan, Gruetter, Rolf, Gupta, Rakesh K., Heerschap, Arend, Henning, Anke, Hetherington, Hoby P., Huppi, Petra S., Hurd, Ralph E., Kantarci, Kejal, Kauppinen, Risto A., Klomp, Dennis W.J., Kreis, Roland, Kruiskamp, Marijn J., Leach, Martin O., Lin, Alexander P., Luijten, Peter R., Marjańska, Małgorzata, Maudsley, Andrew A., Meyerhoff, Dieter J., Mountford, Carolyn E., Mullins, Paul G., Murdoch, James B., Nelson, Sarah J., Noeske, Ralph, Öz, Gülin, Pan, Julie W., Peet, Andrew C., Poptani, Harish, Posse, Stefan, Ratai, Eva Maria, Salibi, Nouha, Scheenen, Tom W.J., Smith, Ian C.P., Soher, Brian J., Tkáč, Ivan, Vigneron, Daniel B., and Howe, Franklyn A.

Published
2019

9. Methodological consensus on clinical proton MRS of the brain: Review and recommendations

Author

Wilson, Martin, Andronesi, Ovidiu, Barker, Peter B., Bartha, Robert, Bizzi, Alberto, Bolan, Patrick J., Brindle, Kevin M., Choi, In‐Young, Cudalbu, Cristina, Dydak, Ulrike, Emir, Uzay E., Gonzalez, Ramon G., Gruber, Stephan, Gruetter, Rolf, Gupta, Rakesh K., Heerschap, Arend, Henning, Anke, Hetherington, Hoby P., Huppi, Petra S., Hurd, Ralph E., Kantarci, Kejal, Kauppinen, Risto A, Klomp, Dennis W. J., Kreis, Roland, Kruiskamp, Marijn J., Leach, Martin O., Lin, Alexander P., Luijten, Peter R., Marjańska, Małgorzata, Maudsley, Andrew A., Meyerhoff, Dieter J., Mountford, Carolyn E., Mullins, Paul G., Murdoch, James B., Nelson, Sarah J., Noeske, Ralph, Öz, Gülin, Pan, Julie W., Peet, Andrew C., Poptani, Harish, Posse, Stefan, Ratai, Eva‐Maria, Salibi, Nouha, Scheenen, Tom W. J., Smith, Ian C. P., Soher, Brian J., Tkáč, Ivan, Vigneron, Daniel B., Howe, Franklyn A., Wilson, Martin, Andronesi, Ovidiu, Barker, Peter B., Bartha, Robert, Bizzi, Alberto, Bolan, Patrick J., Brindle, Kevin M., Choi, In‐Young, Cudalbu, Cristina, Dydak, Ulrike, Emir, Uzay E., Gonzalez, Ramon G., Gruber, Stephan, Gruetter, Rolf, Gupta, Rakesh K., Heerschap, Arend, Henning, Anke, Hetherington, Hoby P., Huppi, Petra S., Hurd, Ralph E., Kantarci, Kejal, Kauppinen, Risto A, Klomp, Dennis W. J., Kreis, Roland, Kruiskamp, Marijn J., Leach, Martin O., Lin, Alexander P., Luijten, Peter R., Marjańska, Małgorzata, Maudsley, Andrew A., Meyerhoff, Dieter J., Mountford, Carolyn E., Mullins, Paul G., Murdoch, James B., Nelson, Sarah J., Noeske, Ralph, Öz, Gülin, Pan, Julie W., Peet, Andrew C., Poptani, Harish, Posse, Stefan, Ratai, Eva‐Maria, Salibi, Nouha, Scheenen, Tom W. J., Smith, Ian C. P., Soher, Brian J., Tkáč, Ivan, Vigneron, Daniel B., and Howe, Franklyn A.

Abstract

Proton MRS (1H MRS) provides noninvasive, quantitative metabolite profiles of tissue and has been shown to aid the clinical management of several brain diseases. Although most modern clinical MR scanners support MRS capabilities, routine use is largely restricted to specialized centers with good access to MR research support. Widespread adoption has been slow for several reasons, and technical challenges toward obtaining reliable good‐quality results have been identified as a contributing factor. Considerable progress has been made by the research community to address many of these challenges, and in this paper a consensus is presented on deficiencies in widely available MRS methodology and validated improvements that are currently in routine use at several clinical research institutions. In particular, the localization error for the PRESS localization sequence was found to be unacceptably high at 3 T, and use of the semi‐adiabatic localization by adiabatic selective refocusing sequence is a recommended solution. Incorporation of simulated metabolite basis sets into analysis routines is recommended for reliably capturing the full spectral detail available from short TE acquisitions. In addition, the importance of achieving a highly homogenous static magnetic field (B0) in the acquisition region is emphasized, and the limitations of current methods and hardware are discussed. Most recommendations require only software improvements, greatly enhancing the capabilities of clinical MRS on existing hardware. Implementation of these recommendations should strengthen current clinical applications and advance progress toward developing and validating new MRS biomarkers for clinical use.

Published
2019
Full Text
View/download PDF

10. Methodological consensus on clinical proton MRS of the brain: Review and recommendations.

Author

Wilson, Martin, Wilson, Martin, Andronesi, Ovidiu, Barker, Peter B, Bartha, Robert, Bizzi, Alberto, Bolan, Patrick J, Brindle, Kevin M, Choi, In-Young, Cudalbu, Cristina, Dydak, Ulrike, Emir, Uzay E, Gonzalez, Ramon G, Gruber, Stephan, Gruetter, Rolf, Gupta, Rakesh K, Heerschap, Arend, Henning, Anke, Hetherington, Hoby P, Huppi, Petra S, Hurd, Ralph E, Kantarci, Kejal, Kauppinen, Risto A, Klomp, Dennis WJ, Kreis, Roland, Kruiskamp, Marijn J, Leach, Martin O, Lin, Alexander P, Luijten, Peter R, Marjańska, Małgorzata, Maudsley, Andrew A, Meyerhoff, Dieter J, Mountford, Carolyn E, Mullins, Paul G, Murdoch, James B, Nelson, Sarah J, Noeske, Ralph, Öz, Gülin, Pan, Julie W, Peet, Andrew C, Poptani, Harish, Posse, Stefan, Ratai, Eva-Maria, Salibi, Nouha, Scheenen, Tom WJ, Smith, Ian CP, Soher, Brian J, Tkáč, Ivan, Vigneron, Daniel B, Howe, Franklyn A, Wilson, Martin, Wilson, Martin, Andronesi, Ovidiu, Barker, Peter B, Bartha, Robert, Bizzi, Alberto, Bolan, Patrick J, Brindle, Kevin M, Choi, In-Young, Cudalbu, Cristina, Dydak, Ulrike, Emir, Uzay E, Gonzalez, Ramon G, Gruber, Stephan, Gruetter, Rolf, Gupta, Rakesh K, Heerschap, Arend, Henning, Anke, Hetherington, Hoby P, Huppi, Petra S, Hurd, Ralph E, Kantarci, Kejal, Kauppinen, Risto A, Klomp, Dennis WJ, Kreis, Roland, Kruiskamp, Marijn J, Leach, Martin O, Lin, Alexander P, Luijten, Peter R, Marjańska, Małgorzata, Maudsley, Andrew A, Meyerhoff, Dieter J, Mountford, Carolyn E, Mullins, Paul G, Murdoch, James B, Nelson, Sarah J, Noeske, Ralph, Öz, Gülin, Pan, Julie W, Peet, Andrew C, Poptani, Harish, Posse, Stefan, Ratai, Eva-Maria, Salibi, Nouha, Scheenen, Tom WJ, Smith, Ian CP, Soher, Brian J, Tkáč, Ivan, Vigneron, Daniel B, and Howe, Franklyn A

Abstract

Proton MRS (1 H MRS) provides noninvasive, quantitative metabolite profiles of tissue and has been shown to aid the clinical management of several brain diseases. Although most modern clinical MR scanners support MRS capabilities, routine use is largely restricted to specialized centers with good access to MR research support. Widespread adoption has been slow for several reasons, and technical challenges toward obtaining reliable good-quality results have been identified as a contributing factor. Considerable progress has been made by the research community to address many of these challenges, and in this paper a consensus is presented on deficiencies in widely available MRS methodology and validated improvements that are currently in routine use at several clinical research institutions. In particular, the localization error for the PRESS localization sequence was found to be unacceptably high at 3 T, and use of the semi-adiabatic localization by adiabatic selective refocusing sequence is a recommended solution. Incorporation of simulated metabolite basis sets into analysis routines is recommended for reliably capturing the full spectral detail available from short TE acquisitions. In addition, the importance of achieving a highly homogenous static magnetic field (B0 ) in the acquisition region is emphasized, and the limitations of current methods and hardware are discussed. Most recommendations require only software improvements, greatly enhancing the capabilities of clinical MRS on existing hardware. Implementation of these recommendations should strengthen current clinical applications and advance progress toward developing and validating new MRS biomarkers for clinical use.

Published
2019

11. Methodological consensus on clinical proton MRS of the brain : Review and recommendations

Author

Wilson, Martin, Andronesi, Ovidiu, Barker, Peter B., Bartha, Robert, Bizzi, Alberto, Bolan, Patrick J., Brindle, Kevin M., Choi, In Young, Cudalbu, Cristina, Dydak, Ulrike, Emir, Uzay E., Gonzalez, Ramon G., Gruber, Stephan, Gruetter, Rolf, Gupta, Rakesh K., Heerschap, Arend, Henning, Anke, Hetherington, Hoby P., Huppi, Petra S., Hurd, Ralph E., Kantarci, Kejal, Kauppinen, Risto A., Klomp, Dennis W.J., Kreis, Roland, Kruiskamp, Marijn J., Leach, Martin O., Lin, Alexander P., Luijten, Peter R., Marjańska, Małgorzata, Maudsley, Andrew A., Meyerhoff, Dieter J., Mountford, Carolyn E., Mullins, Paul G., Murdoch, James B., Nelson, Sarah J., Noeske, Ralph, Öz, Gülin, Pan, Julie W., Peet, Andrew C., Poptani, Harish, Posse, Stefan, Ratai, Eva Maria, Salibi, Nouha, Scheenen, Tom W.J., Smith, Ian C.P., Soher, Brian J., Tkáč, Ivan, Vigneron, Daniel B., Howe, Franklyn A., Wilson, Martin, Andronesi, Ovidiu, Barker, Peter B., Bartha, Robert, Bizzi, Alberto, Bolan, Patrick J., Brindle, Kevin M., Choi, In Young, Cudalbu, Cristina, Dydak, Ulrike, Emir, Uzay E., Gonzalez, Ramon G., Gruber, Stephan, Gruetter, Rolf, Gupta, Rakesh K., Heerschap, Arend, Henning, Anke, Hetherington, Hoby P., Huppi, Petra S., Hurd, Ralph E., Kantarci, Kejal, Kauppinen, Risto A., Klomp, Dennis W.J., Kreis, Roland, Kruiskamp, Marijn J., Leach, Martin O., Lin, Alexander P., Luijten, Peter R., Marjańska, Małgorzata, Maudsley, Andrew A., Meyerhoff, Dieter J., Mountford, Carolyn E., Mullins, Paul G., Murdoch, James B., Nelson, Sarah J., Noeske, Ralph, Öz, Gülin, Pan, Julie W., Peet, Andrew C., Poptani, Harish, Posse, Stefan, Ratai, Eva Maria, Salibi, Nouha, Scheenen, Tom W.J., Smith, Ian C.P., Soher, Brian J., Tkáč, Ivan, Vigneron, Daniel B., and Howe, Franklyn A.

Published
2019

12. Methodological consensus on clinical proton MRS of the brain: Review and recommendations

Author

Highfield Research Group, Brain, Circulatory Health, Regenerative Medicine and Stem Cells, Cancer, Fysica Radiotherapie Research, Divisie Beeld & Oncologie, Divisie Beeld, Wilson, Martin, Andronesi, Ovidiu, Barker, Peter B., Bartha, Robert, Bizzi, Alberto, Bolan, Patrick J., Brindle, Kevin M., Choi, In Young, Cudalbu, Cristina, Dydak, Ulrike, Emir, Uzay E., Gonzalez, Ramon G., Gruber, Stephan, Gruetter, Rolf, Gupta, Rakesh K., Heerschap, Arend, Henning, Anke, Hetherington, Hoby P., Huppi, Petra S., Hurd, Ralph E., Kantarci, Kejal, Kauppinen, Risto A., Klomp, Dennis W.J., Kreis, Roland, Kruiskamp, Marijn J., Leach, Martin O., Lin, Alexander P., Luijten, Peter R., Marjańska, Małgorzata, Maudsley, Andrew A., Meyerhoff, Dieter J., Mountford, Carolyn E., Mullins, Paul G., Murdoch, James B., Nelson, Sarah J., Noeske, Ralph, Öz, Gülin, Pan, Julie W., Peet, Andrew C., Poptani, Harish, Posse, Stefan, Ratai, Eva Maria, Salibi, Nouha, Scheenen, Tom W.J., Smith, Ian C.P., Soher, Brian J., Tkáč, Ivan, Vigneron, Daniel B., Howe, Franklyn A., Highfield Research Group, Brain, Circulatory Health, Regenerative Medicine and Stem Cells, Cancer, Fysica Radiotherapie Research, Divisie Beeld & Oncologie, Divisie Beeld, Wilson, Martin, Andronesi, Ovidiu, Barker, Peter B., Bartha, Robert, Bizzi, Alberto, Bolan, Patrick J., Brindle, Kevin M., Choi, In Young, Cudalbu, Cristina, Dydak, Ulrike, Emir, Uzay E., Gonzalez, Ramon G., Gruber, Stephan, Gruetter, Rolf, Gupta, Rakesh K., Heerschap, Arend, Henning, Anke, Hetherington, Hoby P., Huppi, Petra S., Hurd, Ralph E., Kantarci, Kejal, Kauppinen, Risto A., Klomp, Dennis W.J., Kreis, Roland, Kruiskamp, Marijn J., Leach, Martin O., Lin, Alexander P., Luijten, Peter R., Marjańska, Małgorzata, Maudsley, Andrew A., Meyerhoff, Dieter J., Mountford, Carolyn E., Mullins, Paul G., Murdoch, James B., Nelson, Sarah J., Noeske, Ralph, Öz, Gülin, Pan, Julie W., Peet, Andrew C., Poptani, Harish, Posse, Stefan, Ratai, Eva Maria, Salibi, Nouha, Scheenen, Tom W.J., Smith, Ian C.P., Soher, Brian J., Tkáč, Ivan, Vigneron, Daniel B., and Howe, Franklyn A.

Published
2019

13. Methodological consensus on clinical proton MRS of the brain: Review and recommendations

Author

Wilson, Martin, Andronesi, Ovidiu, Barker, Peter B., Bartha, Robert, Bizzi, Alberto, Bolan, Patrick J., Brindle, Kevin M., Choi, In‐Young, Cudalbu, Cristina, Dydak, Ulrike, Emir, Uzay E., Gonzalez, Ramon G., Gruber, Stephan, Gruetter, Rolf, Gupta, Rakesh K., Heerschap, Arend, Henning, Anke, Hetherington, Hoby P., Huppi, Petra S., Hurd, Ralph E., Kantarci, Kejal, Kauppinen, Risto A, Klomp, Dennis W. J., Kreis, Roland, Kruiskamp, Marijn J., Leach, Martin O., Lin, Alexander P., Luijten, Peter R., Marjańska, Małgorzata, Maudsley, Andrew A., Meyerhoff, Dieter J., Mountford, Carolyn E., Mullins, Paul G., Murdoch, James B., Nelson, Sarah J., Noeske, Ralph, Öz, Gülin, Pan, Julie W., Peet, Andrew C., Poptani, Harish, Posse, Stefan, Ratai, Eva‐Maria, Salibi, Nouha, Scheenen, Tom W. J., Smith, Ian C. P., Soher, Brian J., Tkáč, Ivan, Vigneron, Daniel B., Howe, Franklyn A., Wilson, Martin, Andronesi, Ovidiu, Barker, Peter B., Bartha, Robert, Bizzi, Alberto, Bolan, Patrick J., Brindle, Kevin M., Choi, In‐Young, Cudalbu, Cristina, Dydak, Ulrike, Emir, Uzay E., Gonzalez, Ramon G., Gruber, Stephan, Gruetter, Rolf, Gupta, Rakesh K., Heerschap, Arend, Henning, Anke, Hetherington, Hoby P., Huppi, Petra S., Hurd, Ralph E., Kantarci, Kejal, Kauppinen, Risto A, Klomp, Dennis W. J., Kreis, Roland, Kruiskamp, Marijn J., Leach, Martin O., Lin, Alexander P., Luijten, Peter R., Marjańska, Małgorzata, Maudsley, Andrew A., Meyerhoff, Dieter J., Mountford, Carolyn E., Mullins, Paul G., Murdoch, James B., Nelson, Sarah J., Noeske, Ralph, Öz, Gülin, Pan, Julie W., Peet, Andrew C., Poptani, Harish, Posse, Stefan, Ratai, Eva‐Maria, Salibi, Nouha, Scheenen, Tom W. J., Smith, Ian C. P., Soher, Brian J., Tkáč, Ivan, Vigneron, Daniel B., and Howe, Franklyn A.

Abstract

Proton MRS (1H MRS) provides noninvasive, quantitative metabolite profiles of tissue and has been shown to aid the clinical management of several brain diseases. Although most modern clinical MR scanners support MRS capabilities, routine use is largely restricted to specialized centers with good access to MR research support. Widespread adoption has been slow for several reasons, and technical challenges toward obtaining reliable good‐quality results have been identified as a contributing factor. Considerable progress has been made by the research community to address many of these challenges, and in this paper a consensus is presented on deficiencies in widely available MRS methodology and validated improvements that are currently in routine use at several clinical research institutions. In particular, the localization error for the PRESS localization sequence was found to be unacceptably high at 3 T, and use of the semi‐adiabatic localization by adiabatic selective refocusing sequence is a recommended solution. Incorporation of simulated metabolite basis sets into analysis routines is recommended for reliably capturing the full spectral detail available from short TE acquisitions. In addition, the importance of achieving a highly homogenous static magnetic field (B0) in the acquisition region is emphasized, and the limitations of current methods and hardware are discussed. Most recommendations require only software improvements, greatly enhancing the capabilities of clinical MRS on existing hardware. Implementation of these recommendations should strengthen current clinical applications and advance progress toward developing and validating new MRS biomarkers for clinical use.

Published
2019
Full Text
View/download PDF

14. Metabolite-cycled density-weighted concentric rings k-space trajectory (DW-CRT) enables high-resolution 1 H magnetic resonance spectroscopic imaging at 3-Tesla.

Author

Steel, Adam, Steel, Adam, Chiew, Mark, Jezzard, Peter, Voets, Natalie L, Plaha, Puneet, Thomas, Michael Albert, Stagg, Charlotte J, Emir, Uzay E, Steel, Adam, Steel, Adam, Chiew, Mark, Jezzard, Peter, Voets, Natalie L, Plaha, Puneet, Thomas, Michael Albert, Stagg, Charlotte J, and Emir, Uzay E

Abstract

Magnetic resonance spectroscopic imaging (MRSI) is a promising technique in both experimental and clinical settings. However, to date, MRSI has been hampered by prohibitively long acquisition times and artifacts caused by subject motion and hardware-related frequency drift. In the present study, we demonstrate that density weighted concentric ring trajectory (DW-CRT) k-space sampling in combination with semi-LASER excitation and metabolite-cycling enables high-resolution MRSI data to be rapidly acquired at 3 Tesla. Single-slice full-intensity MRSI data (short echo time (TE) semi-LASER TE = 32 ms) were acquired from 6 healthy volunteers with an in-plane resolution of 5 × 5 mm in 13 min 30 sec using this approach. Using LCModel analysis, we found that the acquired spectra allowed for the mapping of total N-acetylaspartate (median Cramer-Rao Lower Bound [CRLB] = 3%), glutamate+glutamine (8%), and glutathione (13%). In addition, we demonstrate potential clinical utility of this technique by optimizing the TE to detect 2-hydroxyglutarate (long TE semi-LASER, TE = 110 ms), to produce relevant high-resolution metabolite maps of grade III IDH-mutant oligodendroglioma in a single patient. This study demonstrates the potential utility of MRSI in the clinical setting at 3 Tesla.

Published
2018

15. Metabolite-cycled density-weighted concentric rings k-space trajectory (DW-CRT) enables high-resolution 1 H magnetic resonance spectroscopic imaging at 3-Tesla.

Author

Steel, Adam, Steel, Adam, Chiew, Mark, Jezzard, Peter, Voets, Natalie L, Plaha, Puneet, Thomas, Michael Albert, Stagg, Charlotte J, Emir, Uzay E, Steel, Adam, Steel, Adam, Chiew, Mark, Jezzard, Peter, Voets, Natalie L, Plaha, Puneet, Thomas, Michael Albert, Stagg, Charlotte J, and Emir, Uzay E

Abstract

Magnetic resonance spectroscopic imaging (MRSI) is a promising technique in both experimental and clinical settings. However, to date, MRSI has been hampered by prohibitively long acquisition times and artifacts caused by subject motion and hardware-related frequency drift. In the present study, we demonstrate that density weighted concentric ring trajectory (DW-CRT) k-space sampling in combination with semi-LASER excitation and metabolite-cycling enables high-resolution MRSI data to be rapidly acquired at 3 Tesla. Single-slice full-intensity MRSI data (short echo time (TE) semi-LASER TE = 32 ms) were acquired from 6 healthy volunteers with an in-plane resolution of 5 × 5 mm in 13 min 30 sec using this approach. Using LCModel analysis, we found that the acquired spectra allowed for the mapping of total N-acetylaspartate (median Cramer-Rao Lower Bound [CRLB] = 3%), glutamate+glutamine (8%), and glutathione (13%). In addition, we demonstrate potential clinical utility of this technique by optimizing the TE to detect 2-hydroxyglutarate (long TE semi-LASER, TE = 110 ms), to produce relevant high-resolution metabolite maps of grade III IDH-mutant oligodendroglioma in a single patient. This study demonstrates the potential utility of MRSI in the clinical setting at 3 Tesla.

Published
2018

16. Clinical proton MR spectroscopy in central nervous system disorders.

Author

Oz, Gülin, Oz, Gülin, Alger, Jeffry R, Barker, Peter B, Bartha, Robert, Bizzi, Alberto, Boesch, Chris, Bolan, Patrick J, Brindle, Kevin M, Cudalbu, Cristina, Dinçer, Alp, Dydak, Ulrike, Emir, Uzay E, Frahm, Jens, González, Ramón Gilberto, Gruber, Stephan, Gruetter, Rolf, Gupta, Rakesh K, Heerschap, Arend, Henning, Anke, Hetherington, Hoby P, Howe, Franklyn A, Hüppi, Petra S, Hurd, Ralph E, Kantarci, Kantarci, Klomp, Dennis WJ, Kreis, Roland, Kruiskamp, Marijn J, Leach, Martin O, Lin, Alexander P, Luijten, Peter R, Marjańska, Malgorzata, Maudsley, Andrew A, Meyerhoff, Dieter J, Mountford, Carolyn E, Nelson, Sarah J, Pamir, M Necmettin, Pan, Jullie W, Peet, Andrew C, Poptani, Harish, Posse, Stefan, Pouwels, Petra JW, Ratai, Eva-Maria, Ross, Brian D, Scheenen, Tom W, Schuster, Christian, Smith, Ian CP, Soher, Brian J, Tkáč, Ivan, Vigneron, Daniel B, Kauppinen, Risto A, MRS Consensus Group, Oz, Gülin, Oz, Gülin, Alger, Jeffry R, Barker, Peter B, Bartha, Robert, Bizzi, Alberto, Boesch, Chris, Bolan, Patrick J, Brindle, Kevin M, Cudalbu, Cristina, Dinçer, Alp, Dydak, Ulrike, Emir, Uzay E, Frahm, Jens, González, Ramón Gilberto, Gruber, Stephan, Gruetter, Rolf, Gupta, Rakesh K, Heerschap, Arend, Henning, Anke, Hetherington, Hoby P, Howe, Franklyn A, Hüppi, Petra S, Hurd, Ralph E, Kantarci, Kantarci, Klomp, Dennis WJ, Kreis, Roland, Kruiskamp, Marijn J, Leach, Martin O, Lin, Alexander P, Luijten, Peter R, Marjańska, Malgorzata, Maudsley, Andrew A, Meyerhoff, Dieter J, Mountford, Carolyn E, Nelson, Sarah J, Pamir, M Necmettin, Pan, Jullie W, Peet, Andrew C, Poptani, Harish, Posse, Stefan, Pouwels, Petra JW, Ratai, Eva-Maria, Ross, Brian D, Scheenen, Tom W, Schuster, Christian, Smith, Ian CP, Soher, Brian J, Tkáč, Ivan, Vigneron, Daniel B, Kauppinen, Risto A, and MRS Consensus Group

Abstract

A large body of published work shows that proton (hydrogen 1 [(1)H]) magnetic resonance (MR) spectroscopy has evolved from a research tool into a clinical neuroimaging modality. Herein, the authors present a summary of brain disorders in which MR spectroscopy has an impact on patient management, together with a critical consideration of common data acquisition and processing procedures. The article documents the impact of (1)H MR spectroscopy in the clinical evaluation of disorders of the central nervous system. The clinical usefulness of (1)H MR spectroscopy has been established for brain neoplasms, neonatal and pediatric disorders (hypoxia-ischemia, inherited metabolic diseases, and traumatic brain injury), demyelinating disorders, and infectious brain lesions. The growing list of disorders for which (1)H MR spectroscopy may contribute to patient management extends to neurodegenerative diseases, epilepsy, and stroke. To facilitate expanded clinical acceptance and standardization of MR spectroscopy methodology, guidelines are provided for data acquisition and analysis, quality assessment, and interpretation. Finally, the authors offer recommendations to expedite the use of robust MR spectroscopy methodology in the clinical setting, including incorporation of technical advances on clinical units.

Published
2014

17. Clinical Proton MR Spectroscopy in Central Nervous System Disorders

Author

Öz, Gülin, Alger, Jeffry R., Barker, Peter B., Bartha, Robert, Bizzi, Alberto, Boesch, Chris, Bolan, Patrick J., Brindle, Kevin M., Cudalbu, Cristina, Dinçer, Alp, Dydak, Ulrike, Emir, Uzay E., Frahm, Jens, González, Ramón Gilberto, Gruber, Stephan, Gruetter, Rolf, Gupta, Rakesh K., Heerschap, Arend, Henning, Anke, Hetherington, Hoby P., Howe, Franklyn A., Hüppi, Petra S., Hurd, Ralph E., Kantarci, Kejal, Klomp, Dennis W. J., Kreis, Roland, Kruiskamp, Marijn J., Leach, Martin O., Lin, Alexander P., Luijten, Peter R., Marjańska, Małgorzata, Maudsley, Andrew A., Meyerhoff, Dieter J., Mountford, Carolyn E., Nelson, Sarah J., Pamir, M. Necmettin, Pan, Jullie W., Peet, Andrew C., Poptani, Harish, Posse, Stefan, Pouwels, Petra J. W., Ratai, Eva-Maria, Ross, Brian D., Scheenen, Tom W. J., Schuster, Christian, Smith, Ian C. P., Soher, Brian J., Tkáč, Ivan, Vigneron, Daniel B., Kauppinen, Risto A., Öz, Gülin, Alger, Jeffry R., Barker, Peter B., Bartha, Robert, Bizzi, Alberto, Boesch, Chris, Bolan, Patrick J., Brindle, Kevin M., Cudalbu, Cristina, Dinçer, Alp, Dydak, Ulrike, Emir, Uzay E., Frahm, Jens, González, Ramón Gilberto, Gruber, Stephan, Gruetter, Rolf, Gupta, Rakesh K., Heerschap, Arend, Henning, Anke, Hetherington, Hoby P., Howe, Franklyn A., Hüppi, Petra S., Hurd, Ralph E., Kantarci, Kejal, Klomp, Dennis W. J., Kreis, Roland, Kruiskamp, Marijn J., Leach, Martin O., Lin, Alexander P., Luijten, Peter R., Marjańska, Małgorzata, Maudsley, Andrew A., Meyerhoff, Dieter J., Mountford, Carolyn E., Nelson, Sarah J., Pamir, M. Necmettin, Pan, Jullie W., Peet, Andrew C., Poptani, Harish, Posse, Stefan, Pouwels, Petra J. W., Ratai, Eva-Maria, Ross, Brian D., Scheenen, Tom W. J., Schuster, Christian, Smith, Ian C. P., Soher, Brian J., Tkáč, Ivan, Vigneron, Daniel B., and Kauppinen, Risto A.

Abstract

A large body of published work shows that proton (hydrogen 1 [(1)H]) magnetic resonance (MR) spectroscopy has evolved from a research tool into a clinical neuroimaging modality. Herein, the authors present a summary of brain disorders in which MR spectroscopy has an impact on patient management, together with a critical consideration of common data acquisition and processing procedures. The article documents the impact of (1)H MR spectroscopy in the clinical evaluation of disorders of the central nervous system. The clinical usefulness of (1)H MR spectroscopy has been established for brain neoplasms, neonatal and pediatric disorders (hypoxia-ischemia, inherited metabolic diseases, and traumatic brain injury), demyelinating disorders, and infectious brain lesions. The growing list of disorders for which (1)H MR spectroscopy may contribute to patient management extends to neurodegenerative diseases, epilepsy, and stroke. To facilitate expanded clinical acceptance and standardization of MR spectroscopy methodology, guidelines are provided for data acquisition and analysis, quality assessment, and interpretation. Finally, the authors offer recommendations to expedite the use of robust MR spectroscopy methodology in the clinical setting, including incorporation of technical advances on clinical units.

Published
2014
Full Text
View/download PDF

18. Clinical proton MR spectroscopy in central nervous system disorders.

Author

Oz, Gülin, Oz, Gülin, Alger, Jeffry R, Barker, Peter B, Bartha, Robert, Bizzi, Alberto, Boesch, Chris, Bolan, Patrick J, Brindle, Kevin M, Cudalbu, Cristina, Dinçer, Alp, Dydak, Ulrike, Emir, Uzay E, Frahm, Jens, González, Ramón Gilberto, Gruber, Stephan, Gruetter, Rolf, Gupta, Rakesh K, Heerschap, Arend, Henning, Anke, Hetherington, Hoby P, Howe, Franklyn A, Hüppi, Petra S, Hurd, Ralph E, Kantarci, Kantarci, Klomp, Dennis WJ, Kreis, Roland, Kruiskamp, Marijn J, Leach, Martin O, Lin, Alexander P, Luijten, Peter R, Marjańska, Malgorzata, Maudsley, Andrew A, Meyerhoff, Dieter J, Mountford, Carolyn E, Nelson, Sarah J, Pamir, M Necmettin, Pan, Jullie W, Peet, Andrew C, Poptani, Harish, Posse, Stefan, Pouwels, Petra JW, Ratai, Eva-Maria, Ross, Brian D, Scheenen, Tom W, Schuster, Christian, Smith, Ian CP, Soher, Brian J, Tkáč, Ivan, Vigneron, Daniel B, Kauppinen, Risto A, MRS Consensus Group, Oz, Gülin, Oz, Gülin, Alger, Jeffry R, Barker, Peter B, Bartha, Robert, Bizzi, Alberto, Boesch, Chris, Bolan, Patrick J, Brindle, Kevin M, Cudalbu, Cristina, Dinçer, Alp, Dydak, Ulrike, Emir, Uzay E, Frahm, Jens, González, Ramón Gilberto, Gruber, Stephan, Gruetter, Rolf, Gupta, Rakesh K, Heerschap, Arend, Henning, Anke, Hetherington, Hoby P, Howe, Franklyn A, Hüppi, Petra S, Hurd, Ralph E, Kantarci, Kantarci, Klomp, Dennis WJ, Kreis, Roland, Kruiskamp, Marijn J, Leach, Martin O, Lin, Alexander P, Luijten, Peter R, Marjańska, Malgorzata, Maudsley, Andrew A, Meyerhoff, Dieter J, Mountford, Carolyn E, Nelson, Sarah J, Pamir, M Necmettin, Pan, Jullie W, Peet, Andrew C, Poptani, Harish, Posse, Stefan, Pouwels, Petra JW, Ratai, Eva-Maria, Ross, Brian D, Scheenen, Tom W, Schuster, Christian, Smith, Ian CP, Soher, Brian J, Tkáč, Ivan, Vigneron, Daniel B, Kauppinen, Risto A, and MRS Consensus Group

Abstract

A large body of published work shows that proton (hydrogen 1 [(1)H]) magnetic resonance (MR) spectroscopy has evolved from a research tool into a clinical neuroimaging modality. Herein, the authors present a summary of brain disorders in which MR spectroscopy has an impact on patient management, together with a critical consideration of common data acquisition and processing procedures. The article documents the impact of (1)H MR spectroscopy in the clinical evaluation of disorders of the central nervous system. The clinical usefulness of (1)H MR spectroscopy has been established for brain neoplasms, neonatal and pediatric disorders (hypoxia-ischemia, inherited metabolic diseases, and traumatic brain injury), demyelinating disorders, and infectious brain lesions. The growing list of disorders for which (1)H MR spectroscopy may contribute to patient management extends to neurodegenerative diseases, epilepsy, and stroke. To facilitate expanded clinical acceptance and standardization of MR spectroscopy methodology, guidelines are provided for data acquisition and analysis, quality assessment, and interpretation. Finally, the authors offer recommendations to expedite the use of robust MR spectroscopy methodology in the clinical setting, including incorporation of technical advances on clinical units.

Published
2014

19. Clinical Proton MR Spectroscopy in Central Nervous System Disorders

Author

Öz, Gülin, Alger, Jeffry R., Barker, Peter B., Bartha, Robert, Bizzi, Alberto, Boesch, Chris, Bolan, Patrick J., Brindle, Kevin M., Cudalbu, Cristina, Dinçer, Alp, Dydak, Ulrike, Emir, Uzay E., Frahm, Jens, González, Ramón Gilberto, Gruber, Stephan, Gruetter, Rolf, Gupta, Rakesh K., Heerschap, Arend, Henning, Anke, Hetherington, Hoby P., Howe, Franklyn A., Hüppi, Petra S., Hurd, Ralph E., Kantarci, Kejal, Klomp, Dennis W. J., Kreis, Roland, Kruiskamp, Marijn J., Leach, Martin O., Lin, Alexander P., Luijten, Peter R., Marjańska, Małgorzata, Maudsley, Andrew A., Meyerhoff, Dieter J., Mountford, Carolyn E., Nelson, Sarah J., Pamir, M. Necmettin, Pan, Jullie W., Peet, Andrew C., Poptani, Harish, Posse, Stefan, Pouwels, Petra J. W., Ratai, Eva-Maria, Ross, Brian D., Scheenen, Tom W. J., Schuster, Christian, Smith, Ian C. P., Soher, Brian J., Tkáč, Ivan, Vigneron, Daniel B., Kauppinen, Risto A., Öz, Gülin, Alger, Jeffry R., Barker, Peter B., Bartha, Robert, Bizzi, Alberto, Boesch, Chris, Bolan, Patrick J., Brindle, Kevin M., Cudalbu, Cristina, Dinçer, Alp, Dydak, Ulrike, Emir, Uzay E., Frahm, Jens, González, Ramón Gilberto, Gruber, Stephan, Gruetter, Rolf, Gupta, Rakesh K., Heerschap, Arend, Henning, Anke, Hetherington, Hoby P., Howe, Franklyn A., Hüppi, Petra S., Hurd, Ralph E., Kantarci, Kejal, Klomp, Dennis W. J., Kreis, Roland, Kruiskamp, Marijn J., Leach, Martin O., Lin, Alexander P., Luijten, Peter R., Marjańska, Małgorzata, Maudsley, Andrew A., Meyerhoff, Dieter J., Mountford, Carolyn E., Nelson, Sarah J., Pamir, M. Necmettin, Pan, Jullie W., Peet, Andrew C., Poptani, Harish, Posse, Stefan, Pouwels, Petra J. W., Ratai, Eva-Maria, Ross, Brian D., Scheenen, Tom W. J., Schuster, Christian, Smith, Ian C. P., Soher, Brian J., Tkáč, Ivan, Vigneron, Daniel B., and Kauppinen, Risto A.

Abstract

A large body of published work shows that proton (hydrogen 1 [(1)H]) magnetic resonance (MR) spectroscopy has evolved from a research tool into a clinical neuroimaging modality. Herein, the authors present a summary of brain disorders in which MR spectroscopy has an impact on patient management, together with a critical consideration of common data acquisition and processing procedures. The article documents the impact of (1)H MR spectroscopy in the clinical evaluation of disorders of the central nervous system. The clinical usefulness of (1)H MR spectroscopy has been established for brain neoplasms, neonatal and pediatric disorders (hypoxia-ischemia, inherited metabolic diseases, and traumatic brain injury), demyelinating disorders, and infectious brain lesions. The growing list of disorders for which (1)H MR spectroscopy may contribute to patient management extends to neurodegenerative diseases, epilepsy, and stroke. To facilitate expanded clinical acceptance and standardization of MR spectroscopy methodology, guidelines are provided for data acquisition and analysis, quality assessment, and interpretation. Finally, the authors offer recommendations to expedite the use of robust MR spectroscopy methodology in the clinical setting, including incorporation of technical advances on clinical units.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results